USFDA issues Warning Letter to Wockhardt’s step down subsidiary

23 Nov 2016 Evaluate

Wockhardt’s step down subsidiary - CP Pharmaceuticals, Wrexham, United Kingdom, has been issued a Warning Letter by the US Food and Drug Administration (USFDA). Currently, there is no business being conducted from CP Pharmaceuticals to the US Market.

The company has already initiated required steps to address the concerns raised by USFDA and will be responding to the Agency within the prescribed time.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.



Wockhardt Share Price

1360.10 28.75 (2.16%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×